Prognostic factors in patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy

Franceschini, Davide; Paiar, Fabiola; Saieva, Calogero; Bonomo, Pierluigi; Agresti, Benedetta; Meattini, Icro; Greto, Daniela; Mangoni, Monica; Meacci, Francesca; Loi, Mauro; Zei, Giacomo; Livi, Lorenzo; Biti, Giampaolo

doi:10.1007/s11547-015-0586-1

Cited by 8 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The management of HNC is often a clinical challenge, since in more than 60% of patients the disease is locally advanced at diagnosis: a combined modality therapy with surgery, radiotherapy and chemotherapy is generally recommended 15. When the disease is deemed unresectable or an organ-preservation goal is pursued, the current standard treatment is represented by the combination of radiation and chemotherapy 16 .…”

Section: Introductionmentioning

confidence: 99%

Prognostic factors in head and neck cancer: a 10-year retrospective analysis in a single-institution in Italy

Cadoni

Giraldi

Petrelli

et al. 2017

Acta Otorhinolaryngol Ital

101

View full text Add to dashboard Cite

È stata condotta unanalisi retrospettiva su 482 pazienti con diagnosi di tumore testa-collo arruolati presso l ospedale Agostino Gemelli di Roma. Lassociazione tra fattori demografici, clinici e comportamentali con la overall survival (OS), il rischio di ricorrenza ed il rischio di un secondo tumore primitivo è stata stimata usando gli Hazard Ratio (HR) e gli intervalli di confidenza al 95% (CIs). La OS considerando tutte le sedi tumorali è stata del 60%, mentre considerando le singole sedi tumorali è risultata del 49.0% per il cavo orale, 54.8% per lorofaringe, 50.0% per lipofaringe e 63.4% per la laringe. Unetà avanzata alla diagnosi (HR = 1.04; 95% CI: 1.02-1.05) ed un avanzato stadio del tumore (HR = 2.00; 95% CI: 1.41-2.84) sono risultati fattori significativamente associati con la OS. Il rischio di ricorrenza è risultato associato con il consumo di alcolici (HR = 1.73; 95% CI: 1.00-2.97). Il rischio di sviluppare un secondo tumore primitivo è risutlato associato con uno stadio avanzato del tumore primario (HR = 2.75; 95% CI: 1.39-5.44) e con laver fumato per più di 40 anni (HR = 3.68; 95% CI: 1.10-12.30). In conclusione abbiamo notato che la OS differisce tra le sedi tumorali del tumore testa-collo. Lo stadio tumorale è risultato essere associato sia con la OS che con il rischo di sviluppare un secondo tumore primitivo. Il consumo di alcol e di tabacco sono risultati essere fattori prognostici, rispettivamente, per la ricorrenza e per linsorgenza di un secondo tumore primitivo.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic factors in head and neck cancer: a 10-year retrospective analysis in a single-institution in Italy

Cadoni

Giraldi

Petrelli

et al. 2017

Acta Otorhinolaryngol Ital

101

View full text Add to dashboard Cite

show abstract

“…Performance status and age are well-known predictors of survival outcomes in patients with head and neck cancer undergoing RT or chemoradiotherapy [ 17 , 19 , 70 , 93 , 94 ]. Similarly, performance status and age were independent predictors of the 2-year mortality rate of patients with OCC and NOCC, respectively, in our analysis.…”

Section: Discussionmentioning

confidence: 99%

Inflammation Status and Body Composition Predict Two-Year Mortality of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma under Provision of Recommended Energy Intake during Concurrent Chemoradiotherapy

et al. 2022

View full text Add to dashboard Cite

Only few prospective cohort trials have evaluated the risk factors for the 2-year mortality rate between two patient subgroups with locally advanced head and neck squamous cell carcinoma (LAHNSCC): oral cavity cancer with adjuvant concurrent chemoradiotherapy (CCRT) (OCC) and non-oral cavity cancer with primary CCRT (NOCC), under the recommended calorie intake and investigated the interplay among calorie supply, nutrition–inflammation biomarkers (NIBs), and total body composition change (TBC), as assessed using dual-energy X-ray absorptiometry (DXA). Patients with LAHNSCC who consumed at least 25 kcal/kg/day during CCRT were prospectively recruited. Clinicopathological variables, blood NIBs, CCRT-related factors, and TBC data before and after treatment were collected. Factor analysis was performed to reduce the number of anthropometric and DXA-derived measurements. Cox proportional hazards models were used for analysis. We enrolled 123 patients with LAHNSCC (69 with OCC and 54 with NOCC). The mean daily calorie intake correlated with the treatment interval changes in total body muscle and fat. Patients consuming ≥30 kcal/kg/day had lower pretreatment levels but exhibited fewer treatment interval changes in anthropometric and DXA measurements than patients consuming <30 kcal/kg/day. In the multivariate analysis of the 2-year mortality rate, the prognostic influence of the recommended calorie intake could not be confirmed, but different risk factors (performance status, pretreatment platelet-to-lymphocyte ratio, and treatment interval body muscle changes in patients with OCC; age, pretreatment neutrophil-to-lymphocyte ratio, and body fat storage in patients with NOCC) showed independent effects. Therefore, the inflammation status and body composition, but not the recommended calorie supply, contribute to the 2-year mortality rate for patients with LAHNSCC receiving CCRT.

show abstract

“…The reasons for this are influenced by the site of malignant tumor growth, size, tissue origin, degree of differentiation, lymph node metastasis, patient's general condition and other factors, of ISSN 2616-5791 Vol. [14,[16][17][18][19][20]. Li XJ [10] and others reported that there was no significant correlation between lymph node metastasis and age and gender.…”

Section: Treatmentmentioning

confidence: 99%

Progress in the study of lymph node metastasis status of squamous cell carcinoma of the oral and maxillofacial region

2023

AJMHS

View full text Add to dashboard Cite

Oral and Maxillofacial squamous cell carcinoma is one of the more common malignant tumors of the maxillofacial region, which develops a high lymph node metastasis rate due to the specificity of the site of occurrence and the richness of the lymphatic traffic network in the neck. Its treatment is mainly based on surgery and radiotherapy and chemotherapy. There are various views on the selection of the extent of lymph node dissection during surgery, and the literature reports that the depth of infiltration of cancer cells has a great influence on lymphatic metastasis, and the AJCC released the latest version of the TNM staging with the addition of the DOI index in the T stage, which has set the direction for the extent of lymphatic dissection. The impact of metastatic lymph node ENE on healing and the psychological pressure and burden of life faced by postoperative patients are also of great concern. In this article, we review the findings of oral and maxillofacial SCC in recent years.

show abstract

Prognostic factors in patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy

Abstract: Hb nadir during treatment, body mass index, smoking, stage, comorbidities and performance status are prognostic factors of outcome and response to radical treatment with radiochemotherapy.

Cited by 8 publications

References 30 publications

Prognostic factors in head and neck cancer: a 10-year retrospective analysis in a single-institution in Italy

Prognostic factors in head and neck cancer: a 10-year retrospective analysis in a single-institution in Italy

Inflammation Status and Body Composition Predict Two-Year Mortality of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma under Provision of Recommended Energy Intake during Concurrent Chemoradiotherapy

Progress in the study of lymph node metastasis status of squamous cell carcinoma of the oral and maxillofacial region

Contact Info

Product

Resources

About